GLP-3 R

GLP-3R is a research-grade injectable formulation, engineered for experimental exploration of triple incretin agonism targeting GLP-1, GIP, and glucagon receptors in metabolic and obesity models. GLP-3R is an advanced compound that supports investigations into superior weight loss efficacy, energy expenditure enhancement, and comprehensive cardiometabolic improvements compared to dual-agonist predecessors.

Triple Agonist Mechanism

• Simultaneously activates GLP-1 and GIP for insulin secretion and appetite suppression, while glucagon agonism boosts hepatic fat oxidation and thermogenesis, with preclinical data indicating profound reductions in body fat and liver steatosis.

• Research highlights enhanced glycemic control through multi-pathway modulation, preserving beta-cell function and improving insulin sensitivity in diabetes simulation studies.

Weight Management Potential

• Demonstrates superior body weight reduction in trials, driven by synergistic effects on satiety, caloric intake restriction, and increased energy utilization, positioning it as a key tool for obesity pathophysiology research.

• Studies explore preservation of lean mass alongside fat loss, alongside benefits in visceral adiposity and metabolic flexibility.

Broader Metabolic Benefits

• Associated with improvements in lipid profiles, blood pressure, and inflammatory markers, supporting its role in cardiometabolic disease modeling.

• Emerging research examines applications in NAFLD resolution and renal protection through reduced ectopic fat deposition.

For research purposes only. Not intended for human consumption.